Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Revenue: $372.8B (+4.2% YoY) | Net income: $4.6B (down from $8.4B) | Operating income: $8.5B (-38% YoY) | Q4 2024: $97.7B | Healthcare benefits segment challenged
CVS Health Corporation is one of the largest healthcare companies in the United States, formed through a series of major acquisitions that transformed CVS Pharmacy — a retail drugstore chain founded in Lowell, Massachusetts in 1963 — into a vertically integrated healthcare enterprise. Key acquisitions include Caremark Rx (pharmacy benefit management, 2007), Aetna (health insurance, $69 billion, 2018), and Oak Street Health (primary care clinics, 2023). CVS Health's model positions the company as a healthcare touchpoint spanning insurance enrollment, prescription management, and clinical care delivery.\n\nCVS Health's segments include Health Care Benefits (Aetna insurance for employer groups, Medicare, and Medicaid), Health Services (Caremark PBM, specialty pharmacy, infusion), and Pharmacy & Consumer Wellness (retail operations). CVS operates 9,000+ pharmacy locations and is expanding MinuteClinic and HealthHUB formats that co-locate clinical services with pharmacy for primary and chronic care management. The company also operates pharmacy-only conversion locations removing front-end retail to concentrate on health services.\n\nCVS Health reported FY2024 revenue of $372.8 billion (+4.2% YoY) with net income of approximately $4.6 billion. Near-term pressure on Aetna's Medicare Advantage business — elevated medical cost ratios from post-pandemic care utilization — has driven benefit redesigns and market exits. Despite these headwinds, CVS Health's vertically integrated model combining PBM leverage, insurance membership, and retail pharmacy access represents a structurally unique healthcare asset at scale.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.